Sutro Biopharma, Inc.
STRONASDAQHealthcare● Active
$25.41
$-0.68(-2.61%)
Market Cap$245899075
P/E Ratio—
52W High$43.85
52W Low$6.7
Sutro Biopharma, Inc. (STRO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · STRO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.10B | $0.06B | $0.15B | $0.07B | $0.06B |
| Cost of Revenue | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Gross Profit | $0.10B | $0.05B | $0.15B | $0.06B | $0.05B |
| Gross Margin %(computed) | 92.85% | 88.37% | 95.57% | 87.77% | 84.21% |
| Operating Expenses | |||||
| R&D Expenses | $0.17B | $0.25B | $0.18B | $0.14B | $0.10B |
| G&A Expenses | $0.04B | $0.05B | $0.06B | $0.06B | $0.06B |
| Total Operating Expenses | $0.20B | $0.29B | $0.24B | $0.19B | $0.15B |
| Operating Income | ($0.10B) | ($0.24B) | ($0.09B) | ($0.13B) | ($0.10B) |
| Operating Margin %(computed) | -102.41% | -384.34% | -58.07% | -190.26% | -159.22% |
| Interest Income | $0.01B | $0.04B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.04B | $0.03B | $0.02B | $0.00B | $0.00B |
| Income Before Tax | ($0.19B) | ($0.23B) | ($0.09B) | ($0.12B) | ($0.11B) |
| Income Tax Expense | ($0.00B) | $0.00B | $0.02B | $0.00B | $0.00B |
| Net Income | ($0.19B) | ($0.23B) | ($0.11B) | ($0.12B) | ($0.11B) |
| Net Margin %(computed) | -186.45% | -366.62% | -69.47% | -175.89% | -170.55% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-22.49 | $-29.60 | $-17.80 | $-23.50 | $-22.90 |
| Wtd Avg Shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.00B |
| EBITDA | ($0.10B) | ($0.18B) | ($0.07B) | ($0.11B) | ($0.10B) |
| EBITDA Margin %(computed) | -95.26% | -290.85% | -44.18% | -155.03% | -157.66% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Sutro Biopharma, Inc. data
About Sutro Biopharma, Inc. (STRO) Income Statement
Sutro Biopharma, Inc. (STRO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, STRO reported revenue of $0.10B, gross profit of $0.10B (gross margin 92.85%), and net income of ($0.19B) — a net profit margin of -186.45%.
Frequently asked questions
STRO · 4 questionsSutro Biopharma, Inc. (STRO) reported revenue of $0.10B for 2025, up 65.2% year-over-year.
STRO revenueSTRO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09